<SEC-DOCUMENT>0001193125-23-148266.txt : 20230518
<SEC-HEADER>0001193125-23-148266.hdr.sgml : 20230518
<ACCEPTANCE-DATETIME>20230518170206
ACCESSION NUMBER:		0001193125-23-148266
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230516
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230518
DATE AS OF CHANGE:		20230518

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Coherus BioSciences, Inc.
		CENTRAL INDEX KEY:			0001512762
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273615821
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36721
		FILM NUMBER:		23936943

	BUSINESS ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		(650) 649-3530

	MAIL ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioGenerics, Inc.
		DATE OF NAME CHANGE:	20110210
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d480273d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:chrs="http://www.coherus.com/20230516" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-05-16_to_2023-05-16">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-05-16_to_2023-05-16">0001512762</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="chrs-20230516.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-05-16_to_2023-05-16"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-05-16</xbrli:startDate> <xbrli:endDate>2023-05-16</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-05-16_to_2023-05-16">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt:datemonthdayyearen">May 16, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-05-16_to_2023-05-16">COHERUS BIOSCIENCES, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-05-16_to_2023-05-16">001-36721</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-05-16_to_2023-05-16">27-3615821</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br />of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification Number)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-05-16_to_2023-05-16">333 Twin Dolphin Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-05-16_to_2023-05-16">Suite 600</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-05-16_to_2023-05-16">Redwood City</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-05-16_to_2023-05-16">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-05-16_to_2023-05-16">94065</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including Zip Code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-05-16_to_2023-05-16">(650)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-05-16_to_2023-05-16">649-3530</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-05-16_to_2023-05-16">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-05-16_to_2023-05-16">CHRS</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item 8.01. Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;16, 2023, Coherus BioSciences, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC and Citigroup Global Markets Inc. as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell an aggregate of 11,764,706 shares (the &#8220;Firm Shares&#8221;) of its common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;) to the Underwriters (the &#8220;Offering&#8221;). Additionally, under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, for 30 days from the date of the Underwriting Agreement, to purchase up to an additional 1,764,705 shares of Common Stock (the &#8220;Optional Shares,&#8221; and together with the Firm Shares, the &#8220;Shares&#8221;), which the Underwriters have elected to exercise in full. The price to the public in the Offering was $4.25 per share. The Underwriters agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $3.995 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Offering was made under a prospectus supplement and related prospectus filed with the Securities and Exchange Commission pursuant to the Company&#8217;s effective shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (Registration <span style="white-space:nowrap">No.&#160;333-268252).</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;18, 2023, the Company completed the sale and issuance of an aggregate of 13,529,411 shares of Common Stock, including the exercise in full of the Underwriters&#8217; option to purchase additional shares. The Company received net proceeds of approximately $53.5&#160;million, after deducting the Underwriters&#8217; discounts and commissions and estimated offering expenses payable by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. The Company and the Company&#8217;s directors, executive officers and certain stockholders that are affiliated with the Company&#8217;s directors also agreed not to sell or transfer any Common Stock for 45 days after May 16, 2023, with respect to the Company, and 60&#160;days after May&#160;16, 2023, with respect to the other parties, without first obtaining the written consent of J.P. Morgan Securities LLC, on behalf of the Underwriters, subject to certain exceptions as described in the prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the Underwriting Agreement, including the form of lock-up agreement, is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement and <span style="white-space:nowrap">lock-up</span> agreements are not a complete description thereof, and are qualified in their entirety by reference to such exhibit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the opinion of Latham &amp; Watkins LLP relating to the validity of the securities issued in the Offering is filed herewith as Exhibit 5.1. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01. Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit</span><br /><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d480273dex11.htm">Underwriting Agreement, dated as of May&#160;16, 2023, among Coherus BioSciences, Inc. and J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d480273dex51.htm">Opinion of Latham &amp; Watkins LLP</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Consent of Latham &amp; Watkins LLP (included in <a href="d480273dex51.htm">Exhibit 5.1</a>)</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3">Date: May&#160;18, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">COHERUS BIOSCIENCES, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ McDavid Stilwell</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">McDavid Stilwell</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d480273dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COHERUS BIOSCIENCES, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11,764,706 Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Underwriting Agreement </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">May&nbsp;16, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">several Underwriters listed </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citigroup Global Markets Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">388 Greenwich Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Coherus BioSciences, Inc., a Delaware corporation (the &#147;Company&#148;), proposes to issue and sell to the several underwriters listed in
Schedule 1 hereto (the &#147;Underwriters&#148;), for whom you are acting as representatives (the &#147;Representatives&#148;), an aggregate of 11,764,706 shares of common stock, par value $0.0001 per share (the &#147;Common Stock&#148;), of the
Company (the &#147;Underwritten Shares&#148;) and, at the option of the Underwriters, up to an additional 1,764,705 shares of Common Stock (the &#147;Option Shares&#148;). The Underwritten Shares and the Option Shares are herein referred to as the
&#147;Shares.&#148; The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the &#147;Stock.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the Shares, as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Registration Statement</U>. The Company has prepared and filed with the Securities and Exchange Commission (the &#147;Commission&#148;)
under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Securities Act&#148;), a registration statement (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268252),</FONT>
including a prospectus, relating to the Shares. Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the
registration statement at the time of its effectiveness (&#147;Rule 430 Information&#148;), is referred to herein as the &#147;Registration Statement&#148;; and as used herein, the term &#147;Preliminary
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus&#148; means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the Commission pursuant to Rule 424(a)
under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information, and the term &#147;Prospectus&#148; means the prospectus in the form first used (or made available
upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the
&#147;Rule 462 Registration Statement&#148;), then any reference herein to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this
&#147;Agreement&#148;) to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form
<FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be, and any reference to &#147;amend&#148;,
&#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of
1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Exchange Act&#148;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings
given to such terms in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below), the Company
had prepared the following information (collectively with the pricing information set forth on Annex A, the &#147;Pricing Disclosure Package&#148;): a Preliminary Prospectus dated May&nbsp;16, 2023 and each &#147;free-writing prospectus&#148; (as
defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means 6:50 A.M., New York
City time, on May&nbsp;16, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase of the Shares by the Underwriters</U>. (a)&nbsp;The Company agrees to issue and sell the
Underwritten Shares to the several Underwriters as provided in this Agreement, and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally
and not jointly, to purchase from the Company the respective number of Underwritten Shares set forth opposite such Underwriter&#146;s name in Schedule 1 hereto at a price per share (the &#147;Purchase Price&#148;) of $3.995. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company agrees to issue and sell the Option Shares to the several Underwriters as provided in this Agreement, and the
Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the Company the Option Shares at the
Purchase Price less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares. If any Option Shares are to be purchased, the number of Option
Shares to be purchased by each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter
in Schedule 1 hereto (or such number increased as set forth in Section&nbsp;10 hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by the several Underwriters, subject, however, to such adjustments to
eliminate any fractional Shares as the Representatives in their sole discretion shall make. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters may exercise the option to purchase Option Shares at any time in whole, or
from time to time in part, on or before the thirtieth day following the date of the Prospectus, by written notice from the Representatives to the Company. Such notice shall set forth the aggregate number of Option Shares as to which the option is
being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth
full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section&nbsp;10 hereof). Any such notice shall be given at least two business days prior to the
date and time of delivery specified therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company understands that the Underwriters intend to make a public offering of the
Shares as soon after the effectiveness of this Agreement as in the judgment of the Representatives is advisable, and initially to offer the Shares on the terms set forth in the Prospectus. The Company acknowledges and agrees that the Underwriters
may offer and sell Shares to or through any affiliate of an Underwriter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Payment for the Shares shall be made by wire transfer in
immediately available funds to the account specified by the Company to the Representatives in the case of the Underwritten Shares, at the offices of Davis Polk&nbsp;&amp; Wardwell LLP, 1600 El Camino Real, Menlo Park, CA 94025 at 10:00 A.M., New
York City time, on May&nbsp;18, 2023, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option
Shares, on the date and at the time and place specified by the Representatives in the written notice of the Underwriters&#146; election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares is referred to
herein as the &#147;Closing Date&#148; and the time and date for such payment for the Option Shares, if other than the Closing Date, is herein referred to as the &#147;Additional Closing Date.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery
to the Representatives for the respective accounts of the several Underwriters of the Shares to be purchased on such date or the Additional Closing Date, as the case may be, with any transfer taxes payable in connection with the sale of such Shares
duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company (&#147;DTC&#148;) unless the Representatives shall otherwise instruct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company acknowledges and agrees that the Underwriters are acting solely in the capacity of an arm&#146;s length contractual
counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other
person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own
advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and the Underwriters shall have no responsibility or liability to the Company with respect
thereto. Any review by the Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. The Company represents and warrants
to each Underwriter that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Preliminary Prospectus.</I> No order preventing or suspending the use of any Preliminary
Prospectus has been issued by the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and no Preliminary Prospectus, at the
time of filing thereof, contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such
Underwriter through the Representatives expressly for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b)
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as
of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any
Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists
of the information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Issuer Free Writing Prospectus. </I>Other than
the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, used, authorized, approved or referred to and
will not prepare, use, authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication by
the Company or its agents and representatives (other than a communication referred to in clause (i)&nbsp;below) an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document not constituting a prospectus pursuant to
Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the
Representatives. Each such Issuer Free Writing Prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
complied in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required
thereby) and, when taken together with the Preliminary Prospectus accompanying, or delivered prior to delivery of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be,
will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the
Company makes no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter
furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any
Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Registration Statement and
Prospectus.</I> The Registration Statement has been declared effective by the Commission. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to
Section&nbsp;8A of the Securities Act against the Company or related to the offering of the Shares has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration
Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied and will comply in all material respects with the applicable requirements of the Securities Act, and did not and will not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement
thereto and as of the Closing Date and as of the Additional Closing Date, as the case may be, the Prospectus will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information
relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and
agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Incorporated Documents</I>. The documents incorporated by reference in the Registration Statement, the Prospectus and
the Pricing Disclosure Package, when they were filed with the Commission, conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a
material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or
the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Financial Statements.</I> The financial statements (including the
related notes thereto) of the Company and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable
requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations
and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#147;GAAP&#148;) applied on a consistent basis throughout
the periods covered thereby, except in the case of unaudited financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain footnotes as permitted by the applicable rules of
the Commission, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly, in all material respects, the information required to be stated therein; and the other financial information included or
incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly, in all material respects,
the information shown thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>No Material Adverse Change.</I> Since the date of the most recent financial
statements of the Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change in the capital stock (other than the issuance of shares of
Common Stock upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the
Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse
change, or any development that would reasonably be expected to result in a prospective material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects
of the Company and its subsidiaries taken as a whole; (ii)&nbsp;neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its
subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its subsidiaries has sustained any loss
or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute
or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Organization and Good Standing.</I> The Company and each of its
subsidiaries have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their
respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they
are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position,
stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#147;Material Adverse Effect&#148;). The Company does
not own or control, directly or indirectly, any corporation, association or other entity other than (i)&nbsp;any subsidiaries listed on Exhibit 21 to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the most
recently ended fiscal year and (ii)&nbsp;any subsidiaries not required to be listed on Exhibit 21 by Item 601 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Capitalization.</I> The authorized shares of capital stock of the Company conform in all material respects to the
description thereof included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued
and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights that have not been duly waived or satisfied; except as described in or
expressly contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights), warrants or options
to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind
relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the
description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the
Company have been duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (except, in the case of any foreign subsidiary, for directors&#146; qualifying shares) and are owned directly or
indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Stock Options. </I>With respect to the stock options (the &#147;Stock
Options&#148;) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries (the &#147;Company Stock Plans&#148;), (i) each grant of a Stock Option was duly authorized no later than the date on which the grant of such
Stock Option was by its terms to be effective (the &#147;Grant Date&#148;) by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and
any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (ii)&nbsp;each such grant was made in accordance
with the terms of the Company Stock Plans and all other applicable laws and regulatory rules or requirements and (iii)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes)
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Due Authorization.</I> The Company has full right, power and authority to execute and deliver this
Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been
duly and validly taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Underwriting Agreement</I>. This Agreement has been duly authorized, executed and
delivered by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>The Shares. </I>The Shares to be issued and sold by the Company hereunder have been duly
authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform to the descriptions thereof in the Registration Statement, the Pricing
Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Descriptions of the Underwriting Agreement.</I> This Agreement conforms in all material respects to the description
thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>No Violation
or Default.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that,
with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to
which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject; or (iii)&nbsp;in violation of any law
or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in
the aggregate, have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>No Conflicts. </I>The execution, delivery and performance by the
Company of this Agreement, the issuance and sale of the Shares and the consummation of the transactions contemplated by this Agreement will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, or
constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, any
indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of
the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the Company or any of its subsidiaries or
(iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict,
breach, violation or default that would not, individually or in the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>No
Consents Required.</I> No consent, approval, authorization, order, license, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the
Company of this Agreement, the issuance and sale of the Shares and the consummation of the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations,
orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;) and under applicable state securities laws in connection with the purchase and distribution of the Shares by the
Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>Legal Proceedings.</I> Except as described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, there are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or any of its subsidiaries is or may reasonably be expected to become a party or to which any
property of the Company or any of its subsidiaries is or may reasonably be expected to become the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably be expected to have
a Material Adverse Effect; to the knowledge of the Company no such investigations, actions, suits or proceedings are threatened or, to the knowledge of the Company, contemplated by any governmental or regulatory authority or threatened by others;
and (i)&nbsp;there are no current or pending legal, governmental or regulatory investigations, actions, suits or proceedings that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or
the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to
be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>Independent Accountants</I>. Ernst&nbsp;&amp; Young LLP, who has
certified certain financial statements of the Company and its subsidiaries, is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission
and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>Title to
Real and Personal Property.</I> The Company and its subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid and marketable rights to lease or otherwise use, all items of real and personal property
and assets that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially
interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii)&nbsp;would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>Intellectual Property.</I> The Company and its subsidiaries own or possess, or can acquire on reasonable terms,
adequate, valid and enforceable rights to use all patents, trademarks, service marks, trade names, trade dress, domain names, inventions, copyrights and copyrightable works, software, <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade
secrets, data and other unpatented and/or unpatentable systems or procedures), publicity rights, privacy rights, proprietary or confidential information and all other worldwide intellectual property and proprietary rights (including all
registrations and applications for registration of, and all goodwill associated with, any of the foregoing) used in, or necessary for the conduct of their respective businesses as currently conducted and as proposed to be conducted
(&#147;Intellectual Property&#148;), except where not owning, possessing or acquiring any such Intellectual Property, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect; and, to the knowledge of
the Company, the conduct of their respective businesses does not infringe, misappropriate or otherwise conflict in any material respect with any such rights of others. The Company and its subsidiaries have not received any notice of any claim of
infringement or misappropriation of, or conflict with, any such rights of others or any notice challenging the validity, scope, or enforceability of the Intellectual Property or the Company&#146;s or any of its subsidiaries&#146; rights therein,
except in each case, as would not reasonably be expected to result in a Material Adverse Effect. To the knowledge of the Company, no third party has materially infringed, misappropriated or otherwise violated any Intellectual Property owned by or
exclusively licensed to the Company or any of its subsidiaries. All Intellectual Property owned by the Company or its subsidiaries is owned solely by the Company or its subsidiaries and is owned free and clear of all liens, encumbrances, defects or
other restrictions, except those liens, encumbrances, defects or other restrictions that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such Intellectual Property by the Company and its subsidiaries or
(ii)&nbsp;could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. To the knowledge of the Company, all Intellectual Property that is licensed to the Company or its subsidiaries is free and clear of all
liens and free of any restrictions or defects, except those liens, encumbrances or defects that (1)&nbsp;do not materially interfere with the use made and proposed to be made of such Intellectual Property by the Company or any of its subsidiaries or
(2)&nbsp;could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. To the knowledge of the Company, all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Intellectual Property owned by or licensed to the Company and its subsidiaries is valid and enforceable, except where such invalidity or unenforceability would not reasonably be expected to
result in a Material Adverse Effect. The Company and its subsidiaries have complied in all material respects with, and are not in breach nor have received any asserted or threatened claim of breach of any Intellectual Property license, and the
Company has no knowledge of any breach or anticipated breach by any other person of any Intellectual Property license, or any facts that may reasonably result in any claims of any such breach, except in each case, as would not reasonably be expected
to result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries is subject to any judgment, order, writ, injunction or decree of any court or any federal, state, local, foreign or other governmental department, commission,
board, bureau, agency or instrumentality, domestic or foreign, or any arbitrator, nor has the Company or any of its subsidiaries entered into or become a party to any agreement made in settlement of any pending or threatened litigation, that
restricts or impairs its use of any Intellectual Property, other than any such restrictions that could not reasonably be expected to result in a Material Adverse Effect. The Company and its subsidiaries have taken commercially reasonable actions
necessary to maintain and protect all registered Intellectual Property owned by the Company or its subsidiaries, including payment of applicable maintenance fees, filing of applicable statements of use, timely response to office actions, and
disclosure of any required information. The Company and its subsidiaries have taken reasonable steps in accordance with normal industry practice to maintain the confidentiality of all material trade secrets and confidential information owned, used
or held for use by the Company or any of its subsidiaries, and, to the knowledge of the Company, no such trade secrets or confidential information have been disclosed other than to employees, representatives and agents of the Company or any of its
subsidiaries, or parties who are bound by written confidentiality agreements. All founders, key employees and other employees, in each case who are currently with the Company or any of its subsidiaries, involved in the development of material
Intellectual Property for the Company or any of its subsidiaries have signed confidentiality and invention assignment agreements with the Company. No employee contributing to any material Intellectual Property developed for and intended to be owned
by the Company or its subsidiaries has failed to assign all of such employee&#146;s rights, title and interest in such Intellectual Property to the Company or its subsidiaries. No independent contractor contributing to any material Intellectual
Property developed for and intended to be owned by the Company or its subsidiaries has failed to assign all of such independent contractor&#146;s rights, title and interest in such Intellectual Property to the Company or its subsidiaries, or, in the
alternative, granted to the Company a license thereunder as necessary for the conduct of the Company&#146;s and its subsidiaries&#146; business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Cybersecurity; Data Protection</I>. The Company and its subsidiaries&#146; information technology assets and equipment,
computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<U>IT Systems</U>&#148;) are adequate for, and operate and perform in all material respects as required in connection with the operation of
the business of the Company and its subsidiaries as currently conducted, and to the Company&#146;s knowledge, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its
subsidiaries </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
have implemented and maintained all commercially reasonable controls, policies, procedures, and safeguards necessary to maintain and protect their material confidential information and the
integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, household, sensitive, confidential or regulated data (&#147;Data&#148;)) used in connection with their businesses.
Without limiting the foregoing, the Company and its subsidiaries have used commercially reasonable efforts to establish and maintain, and have established, maintained, implemented and complied with, reasonable information technology, information
security, cyber security and data protection controls, policies and procedures, including oversight, access controls, encryption, technological and physical safeguards and business continuity/disaster recovery and security plans that are designed to
protect against and prevent breach, destruction, loss, unauthorized distribution, use, access, disablement, disclosure, misappropriation or modification, or other compromise or misuse of or relating to any information technology system or Data used
in connection with the operation of the Company&#146;s and its subsidiaries&#146; businesses (&#147;Breach&#148;). To the knowledge of the Company, there has been no material Breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <I>Privacy Laws.</I> Except where such noncompliance would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect, the Company and each of its subsidiaries are, and at all prior times were, in compliance with all applicable data privacy and security laws and regulations (including, to the extent applicable, the Health Insurance
Portability and Accountability Act (&#147;HIPAA&#148;), as amended by the Health Information Technology for Economic and Clinical Health Act (the &#147;HITECH Act&#148;) (42 U.S.C. Section&nbsp;17921 et seq.), the European Union General Data
Protection Regulation (the &#147;GDPR&#148;) (EU 2016/679), the GDPR as it forms part of UK law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (the &#147;UK GDPR&#148;), the Data Protection Act 2018 and the California Consumer
Privacy Act (the &#147;CCPA&#148;) (collectively, &#147;Privacy Laws&#148;), judgments, orders, rules and regulations of any court or arbitrator or other governmental or regulatory authority and any other legal obligations, in each case, relating to
the collection, use, transfer, import, export, storage, protection, disposal or disclosure by the Company and its subsidiaries of Personal Data, (collectively, together with the Privacy Laws, &#147;Data Security Obligations&#148;). To ensure
compliance with the Data Security Obligations, and to the extent required by the Privacy Laws, the Company and each of its subsidiaries have in place, comply with, and take commercially reasonable steps reasonably designed to ensure compliance in
all respects with their policies and procedures relating to data privacy and security and the collection, use, transfer, import, export, storage, protection, disposal and disclosure of Personal Data (the &#147;Policies&#148;), except where such
noncompliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. &#147;Personal Data&#148; means: (i)&nbsp;any information which would qualify as &#147;personally identifying information&#148;
under the Federal Trade Commission Act, as amended; (ii)&nbsp;Protected Health Information as defined by HIPAA; (iii) &#147;personal data&#148; as defined by the GDPR or any other similar term; and (iv)&nbsp;any other piece of information that
allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#146;s health or sexual orientation and is regulated under the Privacy Laws. To the knowledge
of the Company, none of such disclosures made or contained in any of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Policies have been inaccurate, misleading, deceptive or in violation of any Privacy Laws or Policies in any material respect, except as would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect. The execution, delivery and performance of this Agreement or any other agreement referred to in this Agreement will not result in a breach of any Privacy Laws or Policies, except as would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. During the past three (3)&nbsp;years, neither the Company nor any of its subsidiaries: (i)&nbsp;has received written notice of any actual or potential
liability under or relating to, or actual or potential violation of, any of the Privacy Laws; (ii)&nbsp;has conducted or paid for, or is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective
action pursuant to any Data Security Obligation; or (iii)&nbsp;is a party to any order, decree, or agreement that imposed or imposes any obligation or liability by any governmental or regulatory authority under any Privacy Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>No Undisclosed Relationships.</I> No relationship, direct or indirect, exists between or among the Company or any of
its subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in the Registration Statement and
the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <I>Investment
Company Act.</I> The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not
be required to register as an &#147;investment company&#148; or an entity &#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the
Commission thereunder (collectively, the &#147;Investment Company Act&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <I>Taxes.</I> The Company and its
subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof (after giving effect to any valid extensions with respect to the filing of tax returns) except for
taxes that are being contested in good faith and for which adequate reserves have been provided in accordance with GAAP or where failure to pay would not reasonably be expected to have a Material Adverse Effect; and except as otherwise disclosed in
the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no material tax deficiency that has been, or would reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their
respective properties or assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <I>Licenses and Permits.</I> Except as disclosed in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, the Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or
foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, except where </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and except as described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, neither the Company nor any of its subsidiaries has received written notice of any revocation or modification of any such license, certificate, permit or authorization or has any reason to believe that any such license,
certificate, permit or authorization will not be renewed in the ordinary course. The Company and its subsidiaries: (i)&nbsp;are, and at all times have been, in material compliance with all statutes, rules and regulations applicable to the ownership,
testing, development, manufacture, packaging, processing, use, distribution, marketing, sale, storage, import, export or disposal of any product manufactured or distributed by the Company or its subsidiaries (&#147;Applicable Laws&#148;), except
where such noncompliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (ii)&nbsp;during the past three (3)&nbsp;years, have not received any U.S. Food and Drug Administration
(&#147;FDA&#148;) Form 483, written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from any court or arbitrator or federal, state, local or foreign governmental or regulatory authority alleging
or asserting <FONT STYLE="white-space:nowrap">non-compliance</FONT> with (x)&nbsp;any Applicable Laws, including the Federal Food, Drug and Cosmetic Act (21 U.S.C &#167; 301 et seq.), or (y)&nbsp;any licenses, exemptions, certificates, approvals,
clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws, except, in each case, as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <I>No Labor Disputes.</I> No labor disturbance by or dispute with employees of the Company or any of its subsidiaries
exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries&#146; principal suppliers,
contractors or customers, except in each case as would not have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>Compliance with and
Liability under Certain Environmental Laws.</I> (i)&nbsp;The Company and its subsidiaries (a)&nbsp;are, and at all prior times were, in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, requirements,
decisions, judgments, decrees, orders and the common law relating to pollution or the protection of the environment, natural resources or human health or safety, including those relating to the generation, storage, treatment, use, handling,
transportation, Release (as defined in Section&nbsp;3(dd) below) or threat of Release of Hazardous Materials (collectively, &#147;Environmental Laws&#148;), (b) have received and are in compliance with all permits, licenses, certificates or other
authorizations or approvals required of them under applicable Environmental Laws to conduct their respective businesses, (c)&nbsp;have not received written notice of any actual or potential liability under or relating to, or actual or potential
violation of, any Environmental Laws, including for the investigation or remediation of any Release or threat of Release of Hazardous Materials, and have no knowledge of any event or condition that would reasonably be expected to result in any such
notice, (d)&nbsp;are not conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Environmental Law at any location, and (e)&nbsp;are not a party to any order, decree or agreement that imposes any obligation or liability under any Environmental Law; (ii)&nbsp;there are no
costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i)&nbsp;and (ii) above, for any such matter, as would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect; and (iii)&nbsp;except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (a)&nbsp;there are no proceedings that are pending, or, to the knowledge of the Company,
contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceedings regarding which it is reasonably believed no monetary sanctions of $100,000 or more
will be imposed, (b)&nbsp;the Company and its subsidiaries are not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws, including the Release or threat of Release of
Hazardous Materials, that would reasonably be expected to have a material adverse effect on the capital expenditures, earnings or competitive position of the Company and its subsidiaries, and (c)&nbsp;none of the Company and its subsidiaries
anticipates material capital expenditures relating to any Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>Hazardous Materials</I>. There has
been no storage, generation, transportation, use, handling, treatment, Release or threat of Release of Hazardous Materials by, relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and its subsidiaries,
any other entity (including any predecessor) for whose acts or omissions the Company or any of its subsidiaries is or would reasonably be expected to be liable) at, on, under or from any property or facility now or previously owned, operated or
leased by the Company or any of its subsidiaries, or at, on, under or from any other property or facility, in violation of any Environmental Laws or in a manner or amount or to a location that could reasonably be expected to result in any liability
under any Environmental Law, except for any violation or liability which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. &#147;Hazardous Materials&#148; means any material, chemical, substance,
waste, pollutant, contaminant, compound, mixture, or constituent thereof, in any form or amount, including petroleum (including crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos and asbestos containing
materials, naturally occurring radioactive materials, brine, and drilling mud, regulated or which can give rise to liability under any Environmental Law. &#147;Release&#148; means any spilling, leaking, seepage, pumping, pouring, emitting, emptying,
discharging, injecting, escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through the environment, or in, into, from or through any building or structure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>Compliance with ERISA.</I> (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3) of the
Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any organization which is a member of a controlled group of corporations within the
meaning of Section&nbsp;414 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;)) has any liability (each, a &#147;Plan&#148;) has been maintained in compliance with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to, ERISA and the Code, except for noncompliance that could not reasonably be
expected to have a Material Adverse Effect; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a
statutory or administrative exemption that could reasonably be expected to result in a material liability to the Company or its subsidiaries; (iii)&nbsp;for each Plan that is subject to the funding rules of Section&nbsp;412 of the Code or
Section&nbsp;302 of ERISA, the minimum funding standard of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, as applicable, has been satisfied (without taking into account any waiver thereof or extension of any amortization period) and is
reasonably expected to be satisfied in the future (without taking into account any waiver thereof or extension of any amortization period); (iv) the fair market value of the assets of each Plan subject to the minimum funding standard of
Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (v) no &#147;reportable event&#148; (within the meaning of
Section&nbsp;4043(c) of ERISA) has occurred or is reasonably expected to occur that either has resulted, or could reasonably be expected to result, in material liability to the Company or its subsidiaries, excluding any reportable event for which
the notice requirements have been waived; (vi)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any material liability under Title IV of ERISA (other than contributions to the Plan or
premiums to the PBGC, in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer plan,&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and (vii)&nbsp;to the knowledge of the Company, there is no
pending audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other governmental agency or any foreign regulatory agency with respect to any Plan that could reasonably
be expected to result in material liability to the Company or its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <I>Disclosure Controls</I>. The
Company and its subsidiaries maintain an effective system of &#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the applicable requirements of
the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods
specified in the Commission&#146;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding
required disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>Accounting Controls.</I> The Company and its subsidiaries maintain
systems of &#147;internal control over financial reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that comply with the applicable requirements of the Exchange Act and have been designed by,
or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s
general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in
accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences and
(v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and is prepared in accordance with the
Commission&#146;s rules and guidelines applicable thereto. Based on the Company&#146;s most recent evaluation of its internal controls over financial reporting pursuant to Rule <FONT STYLE="white-space:nowrap">13a-15(c)</FONT> of the Exchange Act,
except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses in the Company&#146;s internal controls. The Company&#146;s auditors and the Audit Committee of the Board of
Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses, if any, in the design or operation of internal controls over financial reporting which have adversely affected or are reasonably likely to
adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the
Company&#146;s internal controls over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>eXtensible Business Reporting Language</I>. The
interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the
Commission&#146;s rules and guidelines applicable thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Insurance. </I>The Company and its subsidiaries have
insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in commercially reasonable amounts and reasonably insures against such losses and risks as are
adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other
expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage at reasonable cost from similar insurers as may be necessary to continue its business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>No Unlawful Payments.</I> Neither the Company nor any of its
subsidiaries nor any director, officer or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries
has: (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or
indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on
behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or
regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or
anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or
improper payment or benefit. The Company and its subsidiaries have promoted policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws, and have instituted formal written policies and
procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk)
<I>Compliance with Anti-Money Laundering Laws</I>. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the
Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related
or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the &#147;Anti-Money Laundering Laws&#148;), and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries nor any director, officer or
employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any
sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation
as a &#147;specially designated national&#148; or &#147;blocked person&#148;), the United Nations Security Council, the European Union, His Majesty&#146;s Treasury or other relevant sanctions authority (collectively, &#147;Sanctions&#148;), nor is
the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, Cuba, Iran, North Korea, Sudan, Syria, the
<FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, any other Covered Region of Ukraine identified pursuant to Executive Order 14065
and Crimea (each, a &#147;Sanctioned Country&#148;); and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of
such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person (including
any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in and will not
engage in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>No Restrictions on Subsidiaries</I>. No subsidiary of the Company is currently prohibited, directly or indirectly,
under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock, from repaying to the Company any loans or advances to
such subsidiary from the Company or from transferring any of such subsidiary&#146;s properties or assets to the Company or any other subsidiary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <I>No Broker&#146;s Fees.</I> Neither the Company nor any of its subsidiaries is a party to any contract, agreement or
understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection with the
offering and sale of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <I>No Registration Rights</I>. No person has the right to require the Company or
any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares except such rights that have been duly waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <I>No Stabilization.</I> The Company, without giving effect to activities by the Underwriters, has not taken, directly or
indirectly, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <I>Margin Rules</I>. The application of the proceeds received by the Company from the issuance, sale and delivery of the
Shares as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus will not violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <I>Forward-Looking Statements.</I> No forward-looking statement (within the meaning of Section&nbsp;27A of the
Securities Act and Section&nbsp;21E of the Exchange Act) contained or incorporated by reference in the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been
disclosed other than in good faith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <I>Statistical and Market Data.</I> Nothing has come to the attention
of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus are not based on or derived
from sources that are reliable and accurate in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <I>Sarbanes-Oxley Act</I>. There is and has
been no failure on the part of the Company or, to the knowledge of the Company, any of the Company&#146;s directors or officers, in their capacities as such, to comply in all material respects with any applicable provision of the Sarbanes-Oxley Act
of 2002, as amended, and the rules and regulations promulgated in connection therewith (the &#147;Sarbanes-Oxley Act&#148;), including Section&nbsp;402 related to loans, to the extent compliance is required as of the date of this Agreement, and
Sections 302 and 906 related to certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <I>Status under the Securities Act</I>. At the time of filing the
Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Shares
and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) under the Securities
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <I>Clinical Trials</I>. Except as described in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, the clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials conducted by or, to the knowledge of the Company, on behalf of or sponsored by the Company or its subsidiaries, or in which the Company or its subsidiaries
have participated, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as
applicable, were, and if still pending are, being conducted in all material respects in accordance with standard medical and scientific research standards and procedures for products or product candidates comparable to those being developed by the
Company and all applicable statutes and all applicable rules and regulations of the FDA and comparable regulatory agencies outside of the United States to which they are subject, including the European Medicines Agency (collectively, the
&#147;Regulatory Authorities&#148;), and current Good Clinical Practices and Good Laboratory Practices; the descriptions in the Registration Statement, the Pricing Disclosure Package and the Prospectus of the results of such studies and tests are
accurate and complete descriptions in all material respects and fairly present the data derived therefrom; the Company has no knowledge of any other trials not described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, the results of which are inconsistent with or call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus; the Company and its subsidiaries have operated at all
times and are currently in compliance in all material respects with all applicable statutes, rules and regulations of the Regulatory Authorities; neither the Company nor any of its subsidiaries have received any written notices, correspondence or
other communications from the Regulatory Authorities or any other governmental agency requiring or threatening the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
termination, material modification or suspension of any clinical or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials that are described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, other than ordinary course communications with respect to modifications in connection
with the design and implementation of such trials, and, to the Company&#146;s knowledge, there are no reasonable grounds for the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <I>Regulatory Filings</I>. The Company has not failed to file with the Regulatory Authorities any required material
filing, declaration, listing, registration, report or submission with respect to the Company&#146;s product candidates that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus; all such
filings, declarations, listings, registrations, reports or submissions were in material compliance with applicable laws when filed (other than any such instances of <FONT STYLE="white-space:nowrap">non-compliance</FONT> that were subsequently
corrected or amended and accepted by the applicable Regulatory Authority); and no material deficiencies regarding compliance with applicable law have been asserted by any applicable Regulatory Authority with respect to any such filings,
declarations, listings, registrations, reports or submissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Agreements of the Company</U>. The Company covenants and
agrees with each Underwriter that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Required Filings.</I> The Company will file the final Prospectus with the
Commission within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will file
promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for
so long as the delivery of a prospectus is required in connection with the offering or sale of the Shares; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the
Underwriters in New York City as soon as is reasonably possible following the date of this Agreement in such quantities as the Representatives may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Delivery of Copies.</I> The Company will deliver, without charge, (i)&nbsp;to the Representatives, three copies of the
Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith; and (ii)&nbsp;to each Underwriter (A)&nbsp;a conformed copy of the Registration Statement as originally filed
and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto and documents incorporated by reference therein
and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term &#147;Prospectus Delivery Period&#148; means such period of time after the first date of the public offering of the Shares as in the
opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by any Underwriter or
dealer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Amendments or Supplements, Issuer Free Writing Prospectuses.</I>
Before preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement or the Prospectus, whether before or after the time that the
Registration Statement becomes effective, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not prepare, use,
authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably object. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Notice to the Representatives.</I> The Company will advise the Representatives promptly, and confirm such advice in
writing (which may be by email), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective; (iii)&nbsp;when any supplement to the Prospectus, any Issuer
Free Writing Prospectus or any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of
any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information; (v)&nbsp;of the issuance by the Commission of any order suspending the effectiveness of the Registration
Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or the initiation or, to the Company&#146;s knowledge, threatening of any proceeding for that purpose or pursuant to
Section&nbsp;8A of the Securities Act; (vi)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, the Pricing Disclosure Package or any Issuer Free Writing Prospectus as then
amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure
Package or any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading; and (vii)&nbsp;of the receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any
jurisdiction or the initiation or, to the Company&#146;s knowledge, threatening of any proceeding for such purpose; and the Company will use its best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration
Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or suspending any such qualification of the Shares and, if any such order is issued, will obtain as soon as possible
the withdrawal thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Ongoing Compliance.</I> (1)&nbsp;If during the Prospectus Delivery
Period (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company will,
as soon as reasonably possible and in any event within twenty-hour (24)&nbsp;hours, notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such
dealers as the Representatives may designate such amendments or supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so
amended or supplemented will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if at any time prior to the Closing Date
(i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Pricing Disclosure
Package to comply with law, the Company will, as soon as reasonably possible and in any event within twenty-hour (24)&nbsp;hours, notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the
Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and
incorporated by reference therein) as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a
purchaser, be misleading or so that the Pricing Disclosure Package will comply with law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Blue Sky Compliance.</I>
The Company will qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution
of the Shares; <U>provided</U> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify,
(ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Earning Statement. </I>The Company will make generally available to its security holders and the Representatives as
soon as practicable an earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal
quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Clear Market.</I> For a period of 45 days after the date of the
Prospectus, the Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose
of, directly or indirectly, or file with the Commission a registration statement under the Securities Act relating to, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, or publicly
disclose the intention to undertake any of the foregoing, or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or any such other securities,
whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, without the prior written consent of J.P. Morgan Securities LLC, other than
(A)&nbsp;the Shares to be sold hereunder, (B)&nbsp;any shares of Common Stock of the Company issued upon the exercise of options granted under Company Stock Plans described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, <U>provided</U>, that the Company shall cause each recipient of such issuance to execute and deliver to J.P. Morgan Securities LLC an agreement substantially in the form of Exhibit A hereto if such recipient has not already delivered
one, (C)&nbsp;any options and other awards granted under Company Stock Plans described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, <U>provided</U>, that the Company shall cause each recipient of such grant to
execute and deliver to J.P. Morgan Securities LLC an agreement substantially in the form of Exhibit A hereto if such recipient has not already delivered one, (D)&nbsp;the filing by the Company of any registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto relating to the shares of Common Stock granted pursuant to or reserved for issuance under Company Stock Plans described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, (E)&nbsp;the issuance of shares of Common Stock of the Company or other securities (including securities convertible into or exchangeable or exercisable for Common Stock or other securities) in connection with the acquisition by
the Company or any of its subsidiaries of the securities, business, properties or other assets of another person or entity or pursuant to any employee benefit plan assumed by the Company or any of its subsidiaries in connection with any such
acquisition, (F)&nbsp;the issuance of shares of Common Stock of the Company or other securities (including securities convertible into or exchangeable or exercisable for Common Stock or other securities) in connection with joint ventures, license or
collaboration agreements, commercial relationships or other strategic transactions, and (G)&nbsp;the issuance of shares of the Common Stock of the Company in connection with the conversion of the Company&#146;s 1.5% senior convertible notes due
April 2026 outstanding on the date hereof; <U>provided</U> that, in the case of clauses (E)&nbsp;and (F), (i) the aggregate number of shares of Stock of the Company or other securities (including securities convertible into or exchangeable or
exercisable for Stock or other securities) issued or to be issued in all such acquisitions and transactions, on an <FONT STYLE="white-space:nowrap">as-converted,</FONT> <FONT STYLE="white-space:nowrap">as-exchanged</FONT> and <FONT
STYLE="white-space:nowrap">as-exercised</FONT> basis, does not exceed 10% of the outstanding Common Stock of the Company following the issuance and sale of the Shares to be sold hereunder and (ii)&nbsp;the Company shall cause each recipient of such
issuance to execute and deliver to J.P. Morgan Securities LLC an agreement substantially in the form of Exhibit A hereto if such recipient has not already delivered one. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Use of Proceeds.</I> The Company will apply the net proceeds from the sale of the Shares as described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of proceeds.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Stabilization.</I> The Company will not, without giving effect to
activities by the Underwriters, take, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Common Stock and will not take any action
prohibited by Regulation M under the Exchange Act in connection with the distribution of the Securities contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange Listing.</I> The Company will use its best efforts to list, subject to notice of issuance, the Shares on the
Nasdaq Global Market (the &#147;Exchange&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Reports.</I> During a period of three years from the date of this
Agreement, the Company will furnish to the Representatives, as soon as is commercially reasonable after the date they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and copies of
any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports and financial statements to
the Representatives to the extent they are filed on the Commission&#146;s Electronic Data Gathering, Analysis, and Retrieval system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of
each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.
<U>Certain Agreements of the Underwriters</U>. Each Underwriter hereby represents and agrees that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has not used,
authorized use of, referred to or participated in the planning for use of, and will not use, authorize use of, refer to or participate in the planning for use of, any &#147;free writing prospectus,&#148; as defined in Rule 405 under the Securities
Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i)&nbsp;a free writing
prospectus that contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free
Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c) or Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such
underwriter and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i)&nbsp;or (iii), an &#147;Underwriter Free Writing Prospectus&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains
the final terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; <U>provided</U> that Underwriters may use a term sheet substantially in the form of Annex C hereto without the
consent of the Company; <U>provided</U> <U>further</U> that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or substantially concurrently with, the first use of such
term sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It is not subject to any pending proceeding under Section&nbsp;8A of the
Securities Act with respect to the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase the Underwritten Shares on the Closing
Date or the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall
be in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed
with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission for
additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Representations and Warranties.</I> The representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the
statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Downgrade.</I> Subsequent to the earlier of (A)&nbsp;the Applicable Time and (B)&nbsp;the execution and delivery of
this Agreement, if there are any debt securities, convertible securities or preferred stock of or guaranteed by the Company or any of its subsidiaries that are rated by a &#147;nationally recognized statistical rating organization,&#148; as such
term is defined in Section&nbsp;3(a)(62) of the Exchange Act, (i)&nbsp;no downgrading shall have occurred in the rating accorded any such debt securities, convertible securities or preferred stock and (ii)&nbsp;no such organization shall have
publicly announced that it has under surveillance or review, or has changed its outlook with respect to, its rating of any such debt securities, convertible securities or preferred stock (other than an announcement with positive implications of a
possible upgrading). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>No Material Adverse Change.</I> No event or condition of a type described in
Section&nbsp;3(g) hereof shall have occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement
thereto) and the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the
terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Officer&#146;s Certificate.</I> The Representatives shall have
received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is
satisfactory to the Representatives (i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations set forth in
Sections 3(b) and 3(d) hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements and satisfied all
conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the effect set forth in paragraphs (a), (c) and (d)&nbsp;above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Comfort Letters.</I> On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case
may be, Ernst&nbsp;&amp; Young LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory
to the Representatives, containing statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained or
incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus; <U>provided</U>, that the letter delivered on the Closing Date or the Additional Closing Date, as the case may be, shall use a <FONT
STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than two business days prior to such Closing Date or such Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Opinion and Negative Assurance Letter of Counsel for the Company.</I> (i)&nbsp;Latham&nbsp;&amp; Watkins LLP, counsel
for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and negative assurance letter, each, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the
Underwriters, in form and substance reasonably satisfactory to the Representatives, and (ii)&nbsp;Chris Slavinsky, in his capacity as Chief Legal Officer to the Company, shall have furnished to the Representative, his written opinion dated the
Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Underwriters.</I> The
Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement of Davis Polk&nbsp;&amp; Wardwell LLP, counsel for the
Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>No Legal Impediment to Issuance.</I> No action shall have been taken
and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent
the issuance or sale of the Shares; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Good Standing</I>. The Representatives shall have received on and as of the Closing Date or the Additional
Closing Date, as the case may be, satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing as a foreign entity in such other jurisdictions as the
Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange Listing.</I> The Shares to be delivered on the Closing Date or the Additional Closing Date, as the case may
be, shall have been approved for listing on the Exchange, subject to official notice of issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of Exhibit A hereto, between you and the executive officers and directors of the
Company and certain stockholders of the Company listed on Annex B hereto relating to sales and certain other dispositions of shares of Common Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force
and effect on the Closing Date or Additional Closing Date, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Additional Documents.</I> On or
prior to the Closing Date or the Additional Closing Date, as the case may be, the Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>DTC.</I> The Shares shall be eligible for clearance and settlement through DTC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the
provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification
and Contribution</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Underwriters.</I> The Company agrees to indemnify and hold harmless each Underwriter,
its affiliates, agents, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims,
damages and liabilities (including, without limitation, legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out of, or
are based upon, (i)&nbsp;any untrue statement or alleged untrue statement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to
make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus, any &#147;issuer
information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any Pricing Disclosure Package (including any Pricing
Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not
misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any
information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in subsection (b)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company.</I> Each Underwriter
agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the
Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue
statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for
use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been
amended), it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures
appearing in the third paragraph under the caption &#147;Underwriting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice and Procedures.</I> If any suit, action,
proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to either paragraph (a)&nbsp;or (b) above, such person
(the &#147;Indemnified Person&#148;) shall promptly notify the person against whom such indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not
relieve it from any liability that it may have under paragraph (a)&nbsp;or (b) above except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>
<U>further</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under paragraph (a)&nbsp;or (b) above. If any such proceeding shall be brought or
asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified
Person, be counsel to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and
shall pay the reasonable fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the reasonable fees and expenses of such counsel
shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a reasonable time to retain counsel
reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying
Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to
actual or potential differing interest between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more
than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter, its affiliates, agents,
directors and officers and any control persons of such Underwriter shall be designated in writing by the Representatives and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control
persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final
judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an Indemnified
Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected
without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance
with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is
or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory
to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified
Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;or (b) above is unavailable to an Indemnified
Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid
or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hand, and the Underwriters on the other, from the offering of the Shares or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;but also the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such
losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective
proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in
the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares. The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company and the
Underwriters agree that it would not be just and equitable if contribution pursuant to paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any
other method of allocation that does not take account of the equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to
in paragraph (d)&nbsp;above shall be deemed to include, subject to the limitations set forth above, any reasonable legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the
provisions of paragraphs (d)&nbsp;and (e), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the
offering of the Shares exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to paragraphs
(d)&nbsp;and (e) are several in proportion to their respective purchase obligations hereunder and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I><FONT
STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The remedies provided for in this Section&nbsp;7 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in
equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effectiveness of Agreement</U>. This Agreement shall become effective upon the execution and delivery hereof by the parties
hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the
Company, if after the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited
on or by any of the New York Stock Exchange or The Nasdaq Stock Market; (ii)&nbsp;trading of any securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued or guaranteed by the Company shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market;
(iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets
or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on
the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Defaulting Underwriter</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the
Shares that it has agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company on the
terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Shares, then the Company shall be
entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Shares on such terms. If other persons become obligated or agree
to purchase the Shares of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full
business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company
agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this Agreement unless
the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Shares that a defaulting Underwriter agreed but failed to purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be,
does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Shares that such Underwriter agreed to purchase on such date) of the
Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any
arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of
Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Shares to be purchased on such date, or if the Company
shall not exercise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the right described in paragraph (b)&nbsp;above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional
Closing Date, as the case may be, shall terminate without liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability
on the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Payment of Expenses</U><I>.</I>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay
or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares and any taxes
payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package
and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants; (iv)&nbsp;the fees and expenses incurred in
connection with the registration or qualification of the Shares under the state or foreign securities or blue sky laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum
(including the related fees and expenses of counsel for the Underwriters) in an amount not to exceed $10,000 (excluding filing fees);&nbsp;(v) the cost of preparing stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any
registrar; (vii)&nbsp;all expenses incurred by the Company in connection with any &#147;road show&#148; presentation to potential investors, <U>provided</U>, <U>however</U>, that the Underwriters and the Company shall each pay 50% of the cost of
chartering any aircraft to be used in connection with the roadshow by the Company and the Underwriters; and (viii)&nbsp;all expenses and application fees related to the listing of the Shares on the Exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9, (ii) the Company for any reason fails to tender the Shares for
delivery to the Underwriters or (iii)&nbsp;the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriters for all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby;
<U>provided</U>, <U>however</U>, that for purposes of this Section&nbsp;11(b), the Company shall in no event be liable to any of the Underwriters for any other amounts, including, without limitation, damages on account of loss of anticipated profits
from the sale of the Shares. For the avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by any Underwriter that is a defaulting Underwriter for purposes of Section&nbsp;10. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section&nbsp;7 hereof. Nothing in
this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be
deemed to be a successor merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Survival</U>. The respective indemnities, rights of contribution,
representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall
survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where otherwise expressly provided, the term
&#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day other than a day on which banks are permitted or required to be closed in New York City; and (c)&nbsp;the
term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed
or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) <FONT
STYLE="white-space:nowrap">622-8358);</FONT> Attention: Equity Syndicate Desk; and c/o Citigroup Global Markets Inc., 388 Greenwich Street, New York, New York 10013, Attention: General Counsel (fax: (646)
<FONT STYLE="white-space:nowrap">291-1469).</FONT> Notices to the Company shall be given to it at Coherus BioSciences, Inc., 333 Twin Dolphin Drive, Suite 600, Redwood City, California 94065 (fax: (650) 649 3535); Attention: Chief Financial Officer,
with a copy to (which copy shall not constitute notice): Latham&nbsp;&amp; Watkins LLP, 140 Scott Drive, Menlo Park, California 94025 (fax: (650) <FONT STYLE="white-space:nowrap">463-2600);</FONT> Attention: Benjamin A. Potter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Governing Law.</I> This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by
and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed in such state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<I>Counterparts.</I> This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same
instrument. This Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any
counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-34- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Amendments or Waivers.</I> No amendment or waiver of any provision of this Agreement,
nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the
meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Patriot Act</I>. In accordance with the requirements of the USA Patriot Act (Title
III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which
information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank; signature pages follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-35- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">COHERUS BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dennis M. Lanfear</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Dennis M. Lanfear</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted: As of the date first written above</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">For itself and on behalf of the several Underwriters listed in Schedule 1 hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benjamin H. Burdett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Benjamin H. Burdett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director, Head of ECM Healthcare</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CITIGROUP GLOBAL MARKETS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For itself and on behalf of the several Underwriters listed in Schedule 1 hereto.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CITIGROUP GLOBAL MARKETS INC.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Brock</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Michael Brock</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Underwriting Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,235,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,352,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mizuho Securities USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,176,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>a. Pricing Disclosure Package </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1. Free
Writing Prospectus: None </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>b. Pricing Information Provided Orally by Underwriters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Price per share to the public: $4.25 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Number of Shares: 11,764,706 (plus 1,764,705 Option Shares) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions per share: $0.255 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Executive Officers, Directors and Certain Stockholders of the Company </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dennis M. Lanfear </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">McDavid Stilwell </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee N. Newcomer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles W. Newton </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jill O&#146;Donnell-Tormey </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paul Reider </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ali J. Satvat </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark D. Stolper </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kimberly J. Tzoumakas </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mats Wahlstr&ouml;m </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lanfear Revocable Trust </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lanfear Capital Advisors, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leonard Capital, LLC </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex C </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pricing Term Sheet </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representative of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several Underwriters listed in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 to the
Underwriting </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreement referred to below </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan
Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re: Coherus BioSciences, Inc. &#151; Public Offering </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that you, as Representative of the several Underwriters, propose to enter into an underwriting agreement (the &#147;Underwriting Agreement&#148;) with Coherus BioSciences, Inc., a Delaware corporation (the &#147;Company&#148;), providing
for the public offering (the &#147;Public Offering&#148;) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#147;Underwriters&#148;), of shares (the &#147;Securities&#148;) of the common stock, $0.0001 par value per
share, of the Company (the &#147;Common Stock&#148;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Underwriters&#146; agreement to purchase and make the Public Offering of the Securities, and for other good and
valuable consideration, receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of J.P. Morgan Securities LLC on behalf of the Underwriters, the undersigned will not, subject to the exceptions
set forth in this letter agreement (this &#147;Letter Agreement&#148;), during the period beginning on the date of this Letter Agreement and ending at the close of business 60 days after the date of the prospectus relating to the Public Offering
(the &#147;Restricted Period&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of,
directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned
by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) (collectively with the Common Stock, the <FONT
STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Securities&#148;), (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or otherwise, (3)&nbsp;make any demand for, or exercise any right
with respect to, the registration of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or (4)&nbsp;publicly disclose the intention to do any of the foregoing, in each case other than (A)&nbsp;transfers of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities as a bona fide gift or gifts, (B)&nbsp;transfers or dispositions of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities to any trust for the direct or indirect benefit of the
undersigned or the immediate family of the undersigned, (C)&nbsp;transfers or dispositions of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities to any corporation, partnership, limited liability company or other entity, all of the
beneficial ownership interests of which are held by the undersigned or the immediate family of the undersigned, (D)&nbsp;transfers or dispositions of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities by will, other testamentary document
or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the undersigned, (E)&nbsp;transfers of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities to partners, members or stockholders
of the undersigned, or to another partnership, limited liability company, corporation or other business entity that controls, is controlled by or is under common control with the undersigned and (F)&nbsp;transfers that occur by operation of law
pursuant to a qualified domestic order or in connection with a divorce settlement; provided that in the case of any transfer or distribution pursuant to clause (A), (B), (C), (D), (E) or (F), each transferee, donee or distributee shall execute and
deliver to the Representative a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement; and provided, further, that in the case of any transfer, disposition or distribution pursuant to clause (A), (B), (C), (D),
(E) or (F), no filing by any party (donor, donee, transferor or transferee) under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or other public announcement shall be required or shall be made voluntarily in
connection with such transfer or distribution (other than a filing on a Form 5 and, in the case of transfers of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities as a bona fide gift or gifts pursuant to clause (A), a filing on a Form 4,
in each case that is made after the expiration of the Restricted Period) and any such transfer or distribution shall not involve a disposition for value. For purposes of this Letter Agreement, &#147;immediate family&#148; shall mean any relationship
by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, notwithstanding the restrictions imposed by this Letter Agreement, the
undersigned may, without the prior written consent of J.P. Morgan Securities LLC, (i)&nbsp;exercise an option or warrant (including a net or cashless exercise of an option or warrant) to purchase shares of Common Stock, and transfer shares of Common
Stock to the Company to cover tax withholding obligations of the undersigned in connection with any such option exercise, <U>provided</U> that the underlying shares of Common Stock shall continue to be subject to the restrictions on transfer set
forth in this Letter Agreement, (ii)&nbsp;transfer to the Company in connection with the vesting, settlement or exercise of any restricted stock units or other rights to purchase shares of Common Stock (including, in each case, by way of
&#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units or rights, provided that any such
shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement, and provided further that any such restricted stock units or rights are held by the undersigned pursuant to an
agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (iii)&nbsp;transfer any
shares of Common Stock pursuant to a trading plan <FONT STYLE="white-space:nowrap">(&#147;10b5-1</FONT> Trading Plan&#148;) established prior to the date hereof and designed to comply with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under
the Exchange Act (as such rule was in effect at the time any such trading plan was adopted) for the transfer of Common Stock, <U>provided</U> that to the extent a public announcement or filing under the Exchange Act, if any, is required of or
voluntarily made by or on behalf of the undersigned or the Company regarding any such transfer, such announcement or filing shall include a statement to the effect that any transfer was effected pursuant to such
<FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan, and (iv)&nbsp;establish a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan after the date hereof for the transfer of Common Stock, <U>provided</U> that such plan does not
provide for any transfers of Common Stock during the Restricted Period, <U>provided</U> that, with respect to each of (i)&nbsp;and (iii) above, no filing under the Exchange Act or other public announcement shall be required or shall be made
voluntarily in connection with such transfer or disposition during the Restricted Period except as required by law or regulation, <U>provided</U> that to the extent such public announcement or filing under the Exchange Act is required by law or
regulation to be made, such announcement or filing shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in (i)&nbsp;or (iv) above, as the case may be (other than in respect of a required filing under
the Exchange Act in connection with the exercise of an option to purchase Common Stock following such individual&#146;s termination of employment with the Company that would otherwise expire during the Restricted Period, <U>provided</U> that
reasonable notice shall be provided to J.P. Morgan Securities LLC prior to any such filing, and <U>provided</U> <U>further</U> that, for the avoidance of doubt, the underlying shares of Common Stock shall continue to be subject to the restrictions
on transfer set forth in this Letter Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the foregoing precludes the undersigned
from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative
transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic
consequences of ownership, in whole or in part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by
delivery of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Securities, in cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the
Company, and any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this
Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this
Letter Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S.
federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any
recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and
tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representative may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with
the Public Offering, the Representative and the other Underwriters are not making a recommendation to you to enter into this Letter Agreement, and nothing set forth in such disclosures is intended to suggest that the Representative or any
Underwriter is making such a recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if J.P. Morgan Securities LLC, on the one hand, or the
Company, on the other hand, informs the other, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, if the Underwriting Agreement does not become effective by June&nbsp;15, 2023, or if
the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities to be sold thereunder, the undersigned shall be released from all
obligations under this Letter Agreement. The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this Letter Agreement shall be governed by and
construed in accordance with the laws of the State of New York. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>IF AN INDIVIDUAL:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>IF AN ENTITY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>(duly authorized signature)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><I>(please print complete name of entity)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>(please print full name</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>(duly authorized signature)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>(please print full name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d480273dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;5.1 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Scott Drive</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park, California 94025</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel:&nbsp;+1.650.328.4600&nbsp;Fax:&nbsp;+1.650.463.2600</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.lw.com</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g480273lw1.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">FIRM / AFFILIATE OFFICES</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Austin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Milan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Beijing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Munich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Boston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">New&nbsp;York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Brussels</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Orange&nbsp;County</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Century&nbsp;City</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Paris</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">May&nbsp;18, 2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chicago</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Riyadh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dubai</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">San&nbsp;Diego</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">D&#252;sseldorf</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">San&nbsp;Francisco</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Frankfurt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Seoul</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Hamburg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shanghai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Hong&nbsp;Kong</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Silicon&nbsp;Valley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Houston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Singapore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">London</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Tel&nbsp;Aviv</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Los&nbsp;Angeles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Tokyo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Madrid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Washington, D.C.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Coherus BioSciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">333
Twin Dolphin Drive, Suite 600 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redwood City, CA 94065 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-268252</FONT> on Form S-3;
</P></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Up to 13,529,411&nbsp;Shares of Common Stock, par value $0.0001 per share </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the addressee set forth above: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted
as special counsel to Coherus BioSciences, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the proposed issuance of up to 13,529,411&nbsp;shares of common stock of the Company, $0.0001 par value per share
(the &#147;<B><I>Shares</I></B>&#148;). The Shares are included in a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), filed with the
Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) on November&nbsp;8, 2022 (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-268252)</FONT> (as so filed and as amended, the &#147;<B><I>Registration
Statement</I></B>&#148;), a base prospectus dated November&nbsp;17, 2022 included in the Registration Statement (the &#147;<B><I>Base Prospectus</I></B>&#148;), a preliminary prospectus supplement dated May&nbsp;16, 2023 filed with the Commission
pursuant to Rule&nbsp;424(b) under the Act (the &#147;<B><I>Preliminary Prospectus Supplement</I></B>&#148; and together with the Base Prospectus, the &#147;<B><I>Preliminary Prospectus</I></B>&#148;), and a prospectus supplement dated May&nbsp;16,
2023 filed with the Commission pursuant to Rule&nbsp;424(b) under the Act (together with the Base Prospectus, the &#147;<B><I>Prospectus</I></B>&#148;), and an underwriting agreement dated May&nbsp;16, 2023, among J.P. Morgan Securities LLC and
Citigroup Global Markets Inc., as representatives of the several underwriters named in the underwriting agreement, and the Company (the &#147;<B><I>Underwriting Agreement</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being furnished in connection with the requirements of Item&nbsp;601(b)(5) of
<FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus, other than as expressly stated herein with
respect to the issue of the Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;18, 2023 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page&nbsp;
 2
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g480273lw2.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such counsel, we have examined
such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without
having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), and we express no opinion with respect to any other laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have
been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor in the circumstances contemplated by the Underwriting Agreement,
the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company and the Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated May&nbsp;16, 2023 and to the reference to
our firm in the Prospectus under the heading &#147;Legal matters.&#148; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of
the Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Latham&nbsp;&amp; Watkins LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>chrs-20230516.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 5/19/2023 12:37:05 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:chrs="http://www.coherus.com/20230516"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.coherus.com/20230516"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="chrs-20230516_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="chrs-20230516_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>chrs-20230516_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 5/19/2023 12:37:05 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>chrs-20230516_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 5/19/2023 12:37:05 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="chrs-20230516.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g480273lw1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g480273lw1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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3'?LH3DU3]HJ,9S4;)RZ62M__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g480273lw2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g480273lw2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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LG$*U:O-QBJE6I)0C%2K3FX17)#EBVG^BV .P&.1QC!/6OI=O*Q^(7%H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140493898761552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 16, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001512762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 16,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COHERUS BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3615821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Twin Dolphin Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-3530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CHRS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d480273d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="chrs-20230516.xsd" xlink:type="simple"/>
    <context id="duration_2023-05-16_to_2023-05-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-05-16_to_2023-05-16">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-05-16_to_2023-05-16"
      id="Hidden_dei_EntityCentralIndexKey">0001512762</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-05-16_to_2023-05-16">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-05-16_to_2023-05-16">2023-05-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-05-16_to_2023-05-16">COHERUS BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-05-16_to_2023-05-16">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-05-16_to_2023-05-16">001-36721</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-05-16_to_2023-05-16">27-3615821</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-05-16_to_2023-05-16">333 Twin Dolphin Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-05-16_to_2023-05-16">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-05-16_to_2023-05-16">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-05-16_to_2023-05-16">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-05-16_to_2023-05-16">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-05-16_to_2023-05-16">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-05-16_to_2023-05-16">649-3530</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-05-16_to_2023-05-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-05-16_to_2023-05-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-05-16_to_2023-05-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-05-16_to_2023-05-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-05-16_to_2023-05-16">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-05-16_to_2023-05-16">CHRS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-05-16_to_2023-05-16">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-05-16_to_2023-05-16">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ 08BR5I>*NQS     $P(   L
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $&(LE8?'IL,:@0  #L1   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !!B+)6GZ ;\+$"  #B#   #0              @ &M#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( $&(LE:7BKL<P    !,"   +
M  "  8D/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $&(LE8<.&7J/P$  #P"
M   /              "  7(0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !!B+)6)!Z;HJT   #X 0  &@              @ '>$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !!B+)699!YDAD!  #/ P
M$P              @ '#$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"   -%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d480273d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d480273d8k.htm">d480273d8k.htm</File>
    <File>chrs-20230516.xsd</File>
    <File>chrs-20230516_lab.xml</File>
    <File>chrs-20230516_pre.xml</File>
    <File>d480273dex11.htm</File>
    <File>d480273dex51.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d480273d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d480273d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "chrs-20230516_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "chrs-20230516_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "chrs-20230516.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "chrs",
   "nsuri": "http://www.coherus.com/20230516",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d480273d8k.htm",
      "contextRef": "duration_2023-05-16_to_2023-05-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d480273d8k.htm",
      "contextRef": "duration_2023-05-16_to_2023-05-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.coherus.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-23-148266-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-148266-xbrl.zip
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MV]:KG6*R.<;-37?<ZZMZW;B??P!02P,$%     @ 08BR5J$H4[1\!@  ND8
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M/YLO]BX6?YI*<>(Z;U]774;[7ATG?S9<?D=_!D179ME<;)8Y^EA8!\35)7;
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M;^&@S<9!VK!+#2_%!$8@F(1I*599R$A'2 8>"G2/H61"*HO@8+-@8$2SF$!
M_?+$7-"1J^"&01&TN91>TNXX#FE&!AJWIXY+.6;0%/"2N2ZBB@Z@<6!NI5A6
M[KA>S1V7ZMI!E2F4?>9B1+KJ]QA/6/^'1?3:Y97:Y9V[NK'S&[F\:*(C$L9.
M<CP;0(CK)?>8@D E_8!@T8 "N7(<I>[!R@&>YJDM&#J*$;Z:UKD4C@9H8S0%
MTNL#COP E\@I6U(I$0<4#.D+?Z0Z.P9W&Q?RD4)@&<!> ;MH)J4QZ"1">RU"
M.\R71% :"8$9I4F1,\A05 W]@7;@%/^J\_,YT5)\E*9C+L$UJ=T/Z1.+K2[
MS:9,V& RT=/KCUVW0-"_#<"/8!'U@G'/Q3<0>.HI(AF9@$#\6"V4:W-FT(/3
MV(Y9-4:8<OPT6F*D1U1+\OUZ A *_QD@ ;,_5@JGIRDP-KA Y7WHOL=%Q(RH
MPZ)B!/0V\)9*"&I0CH/ -7L \@KF4B1$HD>?N_!#3.Z$FL(!L3LRKWM=PEE"
MF:K2*@: *<T#V&'N_/Z,<G94Q;R"!QY4;4:J;'55@JR;KYB25)+M).?:.O+.
M+VC[4*E4\N7Z2;E61@]>SW5HFJ7LU4EDKY+,J-Q,%BD125VM:5'GXKM/D/66
M%&XE5RN?YJJ6M4;RDW5MVM--R]^2YC%F 2AIU%9*EA(Z1Z^G13#:@6 V \*#
M?\U"9#(;9%&!I$ITIAQ/?MT9^;%6*=0T)@!7KM*-M ]+0QSHC.TP G854 Z7
MRL'6_&G';*F?F0S5(@Z6)&KQ8-. >1(P$]"92LGW9DFLOX_PKM$S&*]1#GNQ
MQV *8>%9R@> 78*BI0)-#4=];/O@>]$(&;&C(A?VF$O,!TMH$DHDK.WZ$D!0
M410;>?-:\'G54VP%8V_ 6[9R239#*^=RVN.NUB-K*U!,*)]#5X>.5 "6,Q<%
M5BP/3D&LEM Z0\2EX[2XSDKSX@:$&9:)<&:PK=,.&[3_!'PJK6%]#[@7]P<"
M$?A2BYL<@^&;.XF*$KI!7Q6TE8E'0' >"&28F027[#&/]7FXN$FL3$M-FU/S
MCN@,1D!3[S^@8K&7RT?<[#2R?>, L&(8 +<HJ)8H,W=:8B-B+BIQAX,LASY2
M=K',5Q@\,H'8TS[;$$(#; B':"IAF[2/Y7-*$F/;LG8-0EWI1^";T%SYEX@D
M]>HH4V27\FD0A=6:]J:T]DC>/<[I=8$5 H.JE$#@#NHEK8/2,RQ&%*NFT4QJ
M$*J[^.,0;*F00,H>XB7289.X5LN3RNSU-X0%.;2*/3:D8#97*.9<DO(1_MG4
M9H%A $RD25OPWIRG5SH#AU=Z5X" 8+;-STW;*DQ'X0@7J)T'MS<A#)A0#$-J
M#YD2MM9TR'L@15;!(A@!*0?9T;6>T>4BZ&F"HQYJ5?,J)2T-&/D/?%Q7XR](
M:9YU3B&LL-4%,;!'3D="1:.4(*_3V.XG%]>1G-_7G(I]_QI3-[YX#*U<8-@*
M(A3.4CN*=0?32'EO6OL!"(,NGKVAH!]&Y&<Z"L[([S3\BJ;NYN9!^Z6*[%J^
M(/CC8*5F\X@WEA(5@3I+T0&//%E$F\[2S=FB5K V8N%D;XD2K4Q.5;;D<YPC
M[$9.<.1D*S!?E$+9B3!9YVC]8@MOKMAKN<.G^\YUJY-OWM_<7#UT6XWHRYO?
MR\9<G*EY,%\<?5 2/3VG.J&VJ3KA]&#5"0JRBXS)(2Y4CKQ-+<*6*X2&=Z(+
M@NK\=LL0?6/EA3<CEX_PWA8'[WPJ?CU7]^DC[SG7KA#.Y>/KZ"((MJQ <:(9
M%#.*)V"P?."K_\MGJBL9$ SXZYED0XG=.27Z#9!.]:14/JXX;&I9A6$(LZWS
M21SE.FB/?H5[2,$A'6Q(.Z."?TT>./>Z1/!YD:XE]#^%J6J'9ZJ:8:K[[<[/
M!X4RE^7*GDG4G$=?:YW0K(X^M'.Y@:8)KQ)I=_1/)YY5JNZ9=O K>8 =@D($
M%4=U<OF:AI2HUR]D&?@8CF-2#28R:*NW3Q-\_31QS)O/CI(F=F-]?2HD6'^6
MFG2"<<;Y4;0RX!_GT>_R?H)N^Y>[J\<OG5;WX*'OP\+9B,"WA@L3ZSVO""F=
M#EU1P^*,W1FQZ5@J,\^EN8F,2V)N$#"!Z6_]<C*32S+90.4GF [H'XSQN%M-
M!X0;^@(VZ7R;<>'*2'#A;DE<_[Y+;+BQ<GVW&3=,5'M[T*JIL'4YXCB$13'[
MGENXBG[A96/YI.P-ZCZ?L?B&MQ2^W,:CV&PR\JI]V<KOJ^\[>0\;>/QM"+F'
MF97[\6G6V!_,N^4?MI3%[6BKBK)(;NUK^@0S=$/N3D G'[ST_EOA$BS[WB.?
M+-/I@T8[TTC=QM@CD9I#SOJ)-/^]/BY=&72LB!;.B_H?BE'_C,SE_P!02P,$
M%     @ 08BR5I1UPZQ=E0  , 0# !    !D-#@P,C<S9&5X,3$N:'1M[+UK
M<]Q&DB[\G1'\#X@YNQMD!*0A)5F^R.L(FI(].BO;"DO>V7F_H;O1)"PTT(,+
M*<ZO/WFMRBH W4V*E*A]M;$Q%KO1A;IDY3V?_/YO;W]Y]</W?WMQ\OR'_;WO
MW[Y\^^K%#R_^Y\'QP^/O_\I_P<=_E>^3[W_\[?D_DA]_/OWMU6^__^=?_OZW
MEV]?_.6'9'\/'CK-JRYO?OC^^<O_3MZ\_<>K%__YE\MBT9U_]\W#KXKJ+TE6
M%F?5?_ZES)?=7VBLU_K8*FO.BNI!5Z^_.UIWSQ+Y>U9W7;WBCY9UU3UHBW_E
MWQW[OY?9JBBOOGM;K/(V^36_3'ZO5QF\Z>35RY]__<^_-,79.;SJ^Q]_>/'^
MO)@570*K2K[_ZX\_?/_7U[BLL0D</[K%&<QI2_[RP^EO?WOQ^Q]ODA]?_O;F
M].6+7T]?O$F3E[^>/DP^]DR.C].OGSY)OSYZFKPYSQIXMEXFI_5J55?)FZZ>
MO_OH,_K^CQ_^J!9Y<]D475&=)2=G39ZOX$N8R1\?[:2$5G[)KOZCFK7K9\=/
MT^31T:/'M!WCI'HK[__A_SY\_3#YI6[.,CB ?-[C+L 3KUZ=XKV;>O=M7),?
M3N%59TW=KY.?RWJ6E<DO6?,N[]KD935_>.<+/VF3W_,U4" <==85%TR*W7E^
MDW7+1\A;OGOR[]><29M?Y TLWY%AWK1)6;1=OMAT&^YD+@50P?P\7_1EGAPG
MYWF3=_6='\7\KW4R3H?[>T"(&]Y_*W3X^)O'0'J+H@4>='*15WU^UV_$?_ZC
M;MZEB?XK.3XZ_OK;.V=^M-4WO7>WM-G?)#\#AZTNB_DYL'SX9W<3*O_P_3XZ
MOGON^@K("C[)JD7R,_"9$@7+=S<ZY2Y_WSTH@$-4-[C5IS7<Y+Y-?BSJ-_,B
MK^9YF])IITF6/,_+[!)$<3*OFW7= "^$>W  C##YC_]S_.3K9R"=UUEUA7]\
M\^PP3=9-O:Y;> %PAJ)MX;;@\MJ\+/$3_)TRM'Z$H175_MZ0PYC762[HWKFL
MF^3RO%XE5W6?X%RS.0GKK$V:B(F;H2+^[D8#%I.=@9@_R[H<F;Y12EJGE,Q9
M*6E1*8%%9TURD96PV'\[>G@$M).L\X:?CO;*:3+N=2I69"-'%]OEE2A$\C/<
M5)AI1QM:K^E0>*! 3J0)7&/80%S28E'@8[#QNIZOS'H")<M,X3<>.WCYP^2M
M?8^?'!TU_C;X%9T(GB1(CR9?YDT#!XV3:GGA_")^]B&_@EXP,3GXY0S6W'=M
M!Z^C8U["6I.SX@+_R)?+?-XY6LO*7#?&S,9.0V;&LY%5TYMT+A_]/N+BE1IP
M=K,K(+=J632K-BF $6=.![TLNO/@3@5* OQHGC<5[@H^L^Z;^7G6RH4<;$R*
M6["LR[*^;#\!$SH&V?+'#[_G9\ (A,N\@9M)ZT15FXG.;0O,%6XOW#LX1%S/
MLBCA7VX_C*Z*W[YX#RNOSNCW*^!*0QXFGPJ%[^\1<XJ'.@'"0H;P[>/'M%L9
M3&Z1XT44NF^ ;?$;@7WT)2U#%4?[[@Z/E5]Q,(<M!XH%%E1>I98&@_=Z[H1#
M^SUJ=8^2@Y]@"Y+O?_KMU[?.P#T'0GC0KK-Y_EU57S;9&H1=_9!MB,>/'S]X
M]/2;1U\].DR__RO^# Z\J.9ESY<*.7F[AIGU0!I-CHM!0JH-R3Q,WO0@IL<G
M9'=(.54'IPXD#!=X#M_(7865IXE_,3Y75,#25S0@?+6$'86M62#1+Y",VSZK
MZ(K_CF+BR>.CDQ3_]\<$Y #\]S29/#UF'D VG>.[$]MI9PR/XKUSTZWR%B2)
M2!&9 @A,-V=W6$6[E=6,4SR/\(Q("1[O6QB ?\TD O=[)0.\AK,I5D65-5=L
MF^#_/G_YWV"<BL]C?R^A__]^#>N[*O/P-N>KP67&C];96?Y@UN39NP>S'%:6
M?Y>5E]E5B\Z1[__V>_+FY?\'%/;X+SHD^5R^^S_?TO_])?G[R^=O__:??P$]
MZM^=%7OZXM>W+WZ_=PX9&/RU(W7A^:L\@XN;9T#=_AH(D9*:DK33E)\<T+$!
MFR+RQX]:OO)=?9CP;H;$E-+3YDT1.S.L8TC^CYX<9)LXEC*GB87@5^-$N/T.
M=.?P2+W"+\;N@6>, ;V.[O5@AO0)#@6;T;0=WX$#N.&K; $R["(KRFQ6P@7N
MUS4J%O_L\Y9NM<HYD("#S3K^^O$D<SC$EX+,K'"!,"3MO@C>3#4LE)MM*#@?
M)B\=@W?"B0\0]:X97**+(D/M=H)<AD?Z]-'!['":BQT8O4E_,'&&CA7!3RJB
M,F)(J.0K.Q*6;HYHTU"HEH$N#UQ4^#'J^4Q.?">V3.AA<A),@@X:^&1OO6Q>
MPSG +W6MSOFF6K!,??Q-?*D,>TP\Z:&DP%^:3T;61;-D_7GA%HD_6]3SGJ\U
M?"IV$?QD9A?6R?;:TWT),TN.'R']_ 24#5QPF[A^\^"Q".=)<B!!*Q3IKF>R
M$.MEP_66/= GZ?1VW:Y4I=@<-<I5=@4[Q]<]I#%8-)\=L4(^MU3/T[%'(2UX
M"W_1]NMU:8F.[B+<M;71[3_JJ>.@_M3E=I/=0=M&>SAZ0$[U9.5Q?P^TQR=W
MKSW:U[K;@MP:S1^_UEF^G8(?)J?9NNA 'O\+?Y2C&4+,>-9W255W,-RRJ)R"
M(EMZGEWP74'V#G<:+O$9B@U\*VT9#[1% ,G.^ .[D>?W@PR3$[HHZZ:H&Z6\
M$Z#.8H[2)\''0=ZW;A-F.1A0S&]5(.SOG6<+;ZZP7$,["UF=477#T_32']X]
MCQ]M\PZ%(SR!;DF06>^3$WO^K^4WSXMV7M9M#Z?^.IN_ Z5.J.$[T/ G;LF"
M2&$8;,#3()6(7[$$9OQ .?8ZENJP)_M[NBE#"7?TU08Y+,X@OS)Q!'W\PQ>Y
M$YYWH+<\_>ZKH^3DX2\/O?=P?^^TZ*Y(;4IQ$8.=_/CK>$36]6OU (0>$;CT
ML>.(+6[0*WGBUO0FV3SJWD.E9,PK%/G] A\%V?'U1>&445 %G)A//<F9']&>
MXH"SK"T<?[2./F";:7*9-0V0G+H G$K1FKNC!ADNH9_]:80+Z'WL+QL^GLH6
MI+JB$FXX#H&\\,^ZJ#IBQ;5WN"R;>A5HB#QANC HJZM^-8.K "L9VSYSU=?K
MNH4M8 9JM@0I\NFS-JG0JAX-TB#G)T:2C[LF'6D@XU >@3/ZM\</O_WVJYN%
M@C^(9%]ZGV7 33<28.1Y_$#*"RF:_*F?FO0BX2JN7T-LABJ3 5&.$F+DK.UX
MV2%!)"6:>VC.K.H>319'0V!W925K2Z A%;B?U8(TK05*] *4!%K*(I^7)/Z$
MV[C3A#FNLRMBKK*Y8Y= =8WHT6#N9(CAF$/WL_A]9$T+)BA_[?@'^WN>;.S3
M..68"7G%<6PD?35H]/"S69XUK;BCX7Z2EJ.'[2,-4V/,<I*O;C*B=U^;9]"/
MLI57]<UJT/$WPC30VJ9'Y66@*C:Y3L*_HJ"8+#F^6,P=T0#U\E"7/KW6T;..
M5CR@6B&AL6N=ZFU*D_/Z$A](G<:9+?[LVT[<,?7^GB@_'6OWRR:;2X!$":<5
MW30,(;'*6L#6U+!90.6P*:R3$4FLLG>Y"'CT6JTGO%8#=IE8_OC-N@/E@W;S
M;B.N<;[+@T</=.Y?_(BW$,<)1 Z:R?G[O)D7[13['G)C8M,%R_7+<R Y$$)P
M8?E2X.=XN^1[=&R3C(*+*WY&<NV<%PU(HP[MU"MC>UCK/S;OX8[IM02^BR+
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M2T&]78,;R;(G2A+]"2XC*M^>[B-=VCE&QQ06]M3&22)>[?+I)+"I<PYR/,^
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M4@(\HW1'CRX23(R$"9:5(4^4[&;\)X@\H!C"'V3]'H<7%588!R';LGJ 57]
MWH552'SMHX.L=N8"H8590V'B<"=W20"R_585)-K[5:^=VA@BLZ\HMV8*[!>(
M.9.V?*SMN3(@O-0(+Z-]#USNE0^#H7HFY^/)=.<&-5G3X&8A7\]150DJ1_V-
M,$C'18"V-;5C48_FZUR$#;?@,V[+?OSTB]?@SN3 V1G) =-'7.7 CCV!50P
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MSO?(@G.UT0*G&7P795&2_1M-@>%('D@04K.U/S@'^R:L7;T'#D4$$Y1 M[W
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MN>@8.:S;V"YC<RVE0[IO,"4'NU83.@J[*,*W'5K40I^HF]@](T4NN,+2>(=
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MZ^!60';^H3(S)C7'*FKH*G&X^&9R(0BT#5I]CQ_ P F_LZ*6K,M^"#^F_<2
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MEVT0<QB*7U!7/HH4M3Y3FB/FO\("D9(-P!X&N++/6)@YFD?&\\A1,E4OT L
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M0]\N#/M3Z>. ]^YI#WCB[Y\Z@<V/+\9_]Q1*B?E_:K#;MQ?*NU-"XSKMN#U
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M/:^(;WC,, '],:%CR9[U,6P#=!N3_^3O\^1&R#%02"1PM]M$NND4]'=\+ 6
MY94GA@#D-U0^LE#%@*T J"#0%+""D'TRT(G"*_;$)*Q?B,6D(CYDUR+2MPML
M]$F [68<_9K<V(@W;L#KCY3?5U6_P82#^@'W,1[@SR%# 4>1]+F:&+VW52?)
M?H^XU#IHZW4@Y8VS3@I%B)X/QX"&(]#D6U 'T!%Y&CAB]/]E$_TA (V)?9&4
ME7T-= _A$HA+AA5(822C_:<T!.=A@0LIK >50M-W@#)A+/0ST"4,XV1T"QW]
M(=0'Y&-Y>W-3YQ8BH(72*7B$VV*F6,)9S-%4SX6KCUJ=SQ #]I-2_7$?-L^!
MZ=I7(P"_A5D+ +R5:.N'#%HI:.N]&9TK_>'+-8SIG?^U]?=REJ3^I+7ZTR?]
MW]J'FK9Q;K9O!^W>W^Y[U\WCP.<R9B\<R3V-3Y9!LQ)JM[]Y<:?86[;M_-ZI
MM.5[IV\(2;YII>\3<^]PU,"2YDSBUCM+9K8[9U]AAX\-NGYN\EMG\0@:=PT.
MOT=,81KKN]"18YK&VR'M<=Z5V#,%V%I+#EF+<P<606RT+2( K'@,:>?) X+=
M7$12[]8P'Y/#:@VDH@! PP&,X2/N #W31!J@H)#S>%!F"(L1K+ ")^O$8KVR
MX(7:1%""8@413T04IE/ %V$,#1LP;5W 'BA7P!HDT499VPL:,-VD:\B$O2LH
MB5)<,5_7NV9B;NF"X6*D0F3#B\6 LU'66E?-[M;B/F,Q1"9!6]>/!#BB"8RY
M@('Z"\I?/QK^E@!J!,^QT+7=%G0C7>R-Y:QJ; G36XB5"(,DUA$J1*B;#&M%
M;&;T<C&" )HP/U$%</KR/!U3Z=20P3,W K>:.4I'JS#+AT(\+BA"N?+5"&-L
MC+4*18TG+UVV)!:!N&/!]@7+&1 :,N VBJE W,.PHT MXS$=V%H&7:Y<,IRO
MANH8*JD*H=K,=8E<9^1PZ413J(8ZYG6=G0:>KHV6TO8>"-K498U$013UUHHE
MQ(VU$ED:B4:0&1+\K.FC&:%+@7C#%CH>Q/54CT[9DG;KY(<,IV+N FEC )@6
M(P^N LK-I/7-9L87?@[R'H48>BQO&YE:_]=[J*,;2/SQ&*+U"='#H5Y.U]"J
M?3=V!%OJ'1_<BB;3[<M*=-I86P(2H@VVJ1A\*YIJU1RX\.8F^]!0 ($>, 49
M(3F!_5H_!URH=)%/Y"?0S27V10/@YQ-/C'\( G^#UA5C4</U$&!MA(FYO7?=
MT?*AAZ=TCG&0A'>(+2"JG\*?T% JK#"P@8<X5@%PP.IY.J47 ]/D3*5?="UM
MK>VFX@IE&UN-TK; X!ZM 8QLQND)#7'.]P%4]>][8NK6S0B])V>*-",ID4Z/
M0?B'B[>4WPS<TV77O6N^-H.M;?X!?/ =&-Q(IXR\P,5&0V)*7G;P$T9U0)G:
MT84 6Y8I.SE#N(^YKG&V UC67%=@G!K$P5QWIV@!#/49LZ^A# 2![&,!^0_F
MC3TUFT!Q7QB8JSC472M=WX2'T?9CPC'Q#"!A,%8QR-I91>GA9FV:UN)IHAMG
M*:_H$773;;MR^S.OY3'#=_X&J_*6/\%Z[C=7YA@B><3U)_YZJ<\1O2 YL[L.
M+K_SAQ=_[I'GD3J")@RBVP[4[^DT.",/-'P$3@3\N^W$T(R19/L\"<W97>L+
MW-2_@/P_4$L! A0#%     @ 08BR5B>QEX$\ P  2@L  !$
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M,V1E>#$Q+FAT;5!+ 0(4 Q0    ( $&(LE:F;OF"@@L   @Y   0
M      "  1JW  !D-#@P,C<S9&5X-3$N:'1M4$L%!@     &  8 ?0$  ,K"
$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
